2 completed, 1 terminated, 1 unknown. 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Empagliflozin10Mg Tab: new trials by email Literature Review of Empagliflozin10Mg Tab trials Research Report on Empagliflozin10Mg Tab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab - Heart Failure | Not applicable | Completed | Rehab Werida | 180 | 2025-01-01 | 2026-06-02 |
| Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels Empagliflozin10Mg Tab - Hematocrit Change, Cardiovascular Prevention | Unknown | Aristotle University Of Thessaloniki | 40 | 2023-11-30 | 2024-02-29 | |
| Empagliflozin in Heart Failure Dialysis Patients Empagliflozin10Mg Tab - Heart Failure, Hemodialysis | Not applicable | Completed | Shahid Beheshti University of Medical Sciences | 30 | 2023-06-01 | 2025-06-06 |
| CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients Empagliflozin10Mg Tab, Placebo - Kidney Transplant; Complications, Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Duke University | 20 | 2022-07-25 | 2026-02-27 |
Heart Failure (2) · Diabetes Mellitus, Type 2 (1)
Aristotle University Of Thessaloniki (1) · Duke University (1) · Rehab Werida (1) · Shahid Beheshti University of Medical Sciences (1)
Greece (1) · Iran (1) · Saudi Arabia (1) · United States (1)
Lamiaa Khedr, Ass Prof. (1) · Myles Wolf, MD (1)
PMID 25081992, PMID 26981940, PMID 27470878, PMID 28605608, PMID 30415602, PMID 30862658